Multiple myeloma (MM) is monitored using bone marrow-based minimal residual disease (MRD) assays, which provide high sensitivity but require repeated invasive sampling and are limited to a single anatomical site. Cell-free DNA (cfDNA) offers a minimally invasive alternative, yet most cfDNA approaches rely on prior tumo...
Palak Bajaj, D. Abelman, P. Luo et al.· Blood Advances· 0 citations
Background. Patients with advanced non-small cell lung cancer (NSCLC) and high PD-L1 (>50%) expression show improved outcomes with immune checkpoint inhibitors compared to chemotherapy. We hypothesized that concurrent durvalumab and radiotherapy (RT) without concurrent chemotherapy would be safe and feasible in patient...
Steven H. Lin, S. L. Pugh, D. D. Del Valle et al.· International Journal of Rad...· 0 citations
Immunotherapy transformed cancer treatment, yet precise correlates of response remain to be defined. While intratumoral follicular helper like (Tfhl) CD4 T cells and IgG1+ B cells have been associated with improved outcomes to PD-1 blockade for hepatocellular carcinoma (HCC), their mechanisms contributing to response a...
A. Vaidya, Étienne Humblin, Nataliya Prokhnevska et al.· bioRxiv· 0 citations
In conclusion, integrated coding-noncoding analysis is established as a strategic approach for discovering functional ncRNAs from transcriptomic sequencing data.
Marina E. Michaud, Denis J. Ohlstrom, Mojtaba Bakhtiari et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
